Omeros Corporation - fluxo de caixa trimestral (NASDAQ:OMER) | MetaTrader

Abrir gráfico completo

Financials

Visão geral Relatórios Estatísticas

Total assets 277.08 M235.16 M200.57 M185.71 M325.63 M Total liabilities 264.08 M246.68 M240.79 M244.81 M142.37 M Total equity -182.61 M-213.55 M-228.69 M-220.48 M-121.23 M Total liabilities & shareholders' equities 277.08 M235.16 M200.57 M185.71 M325.63 M Total debt 188.31 M185.89 M167.8 M176.59 M68.93 M Net debt 98.22 M133.49 M139.1 M140.49 M-102.87 M

Notícias

Does Omeros (OMER) Have the Potential to Rally 266.67% as Wall Street Analysts Expect?

Omeros: Making The Bull Case On Q4 Earnings, Ahead Of Key Q1 Commercial Updates (OMER)

Omeros Corporation (OMER) Q4 2025 Earnings Call Transcript

Omeros Corporation supera expectativas com lucro surpreendente no 4º tri de 2025

Omeros: Yartemlea Can Own The Label And Still Split The Market (NASDAQ:OMER)

Ações da Omeros sobem com início dos primeiros envios comerciais de YARTEMLEA

Omeros stock rises as first commercial YARTEMLEA shipments begin

Omeros begins commercial distribution of TA-TMA treatment Yartemlea

Omeros VP Borges sells $750k in shares

Omeros Corporation (OMER) Discusses FDA Approval and Commercialization Plans for YARTEMLEA in TA-TMA Treatment Transcript

Omeros Gets FDA Approval for YARTEMLEA as First Therapy for TA-TMA

Omeros: Why The Novo Nordisk Deal Is More Important Than FDA Approval (NASDAQ:OMER)